President Trump’s endorsement of an experimental Covid-19 drug from
Regeneron Pharmaceuticals Inc.
has raised expectations for a type of medicine that could be authorized for public use within weeks or even days.
Regeneron is racing against rival
Eli Lilly & Co.
to bring the first monoclonal antibody drug on the market to treat Covid-19 patients who aren’t sick enough to be hospitalized. Both companies said Wednesday they had asked the U.S. Food and Drug Administration to authorize use, and they had already made tens of thousands of doses for patients.
If greenlighted, the shots would begin to fill a big hole in the Covid-19 medicine chest for treatment of early and less-severe cases. After more testing, they could offer temporary protection against infections until vaccines arrive. But supply is unlikely to meet demand until next year at the earliest.
Monoclonal antibodies, which are also used